Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.

Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, Karlin L, Brisou G, Vercasson M, Hospital-Gustem C, Schwiertz V, Ranchon F, Rioufol C, Choquet M, Sujobert P, Ghergus D, Bouafia F, Golfier C, Lequeu H, Lazareth A, Novelli S, Devic P, Traverse Glehen A, Viel S, Venet F, Mialou V, Hequet O, Chauchet A, Arkam Y, Nicolas-Virelizier E, Peyrade F, Cavalieri D, Ader F, Ghesquières H, Salles G, Bachy E.